$6.50-0.11 (-1.59%)
News25/Ratings12
News · 26 weeks45-90%
2025-10-262026-04-19
Mix2690d
- Insider9(35%)
- SEC Filings7(27%)
- Other5(19%)
- Offering2(8%)
- Earnings2(8%)
- Analyst1(4%)
Latest news
25 items- PRQ32 Bio to Participate in the 25th Annual Needham Virtual Healthcare ConferenceWALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent
- SECSEC Form 8-K filed by Q32 Bio Inc.8-K - Q32 Bio Inc. (0001661998) (Filer)
- SECSEC Form 424B5 filed by Q32 Bio Inc.424B5 - Q32 Bio Inc. (0001661998) (Filer)
- INSIDERSEC Form 4 filed by Violette Shelia M.4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Kalowski Lee4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Morrison Jodie Pope4 - Q32 Bio Inc. (0001661998) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)
- SECSEC Form S-8 filed by Q32 Bio Inc.S-8 - Q32 Bio Inc. (0001661998) (Filer)
- SECSEC Form 10-K filed by Q32 Bio Inc.10-K - Q32 Bio Inc. (0001661998) (Filer)
- SECQ32 Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Q32 Bio Inc. (0001661998) (Filer)
- PRQ32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 ---- Completed $10.5 million registered direct offering (RDO) ---- Completed asset sale of Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics to further enable Company's strategic focus on advancing bempikibart for alopecia areata (AA) ---- Cash and cash equivalents of $48.3 million as of December 31, 2025, combined with gross proceeds from RDO and guaranteed near-term milestone payments from ADX-097 asset sale, expected to provide financial runway into Q4'27 --WALTHAM, Mass., March 10, 2026 /PRNew
- INSIDERCEO Morrison Jodie Pope sold $44,675 worth of shares (9,896 units at $4.51), decreasing direct ownership by 10% to 89,104 units (SEC Form 4)4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERChief Scientific Officer Violette Shelia M. sold $12,708 worth of shares (2,815 units at $4.51), decreasing direct ownership by 5% to 55,569 units (SEC Form 4)4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERCFO and President Kalowski Lee sold $18,035 worth of shares (3,995 units at $4.51), decreasing direct ownership by 10% to 35,943 units (SEC Form 4)4 - Q32 Bio Inc. (0001661998) (Issuer)
- ANALYSTH.C. Wainwright initiated coverage on Q32 Bio with a new price targetH.C. Wainwright initiated coverage of Q32 Bio with a rating of Buy and set a new price target of $13.00
- SECSEC Form SCHEDULE 13G filed by Q32 Bio Inc.SCHEDULE 13G - Q32 Bio Inc. (0001661998) (Subject)
- PRAlopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsightThe alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar
- SECSEC Form SCHEDULE 13G filed by Q32 Bio Inc.SCHEDULE 13G - Q32 Bio Inc. (0001661998) (Subject)
- PRQ32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceWALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targe
- SECSEC Form 8-K filed by Q32 Bio Inc.8-K - Q32 Bio Inc. (0001661998) (Filer)
- SECSEC Form 424B5 filed by Q32 Bio Inc.424B5 - Q32 Bio Inc. (0001661998) (Filer)
- PRQ32 Bio Announces $10.5 Million Registered Direct OfferingWALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced a $10.5 million registered direct offering. This transaction was led by a new institutional investor with participation by an existing dedicated public institutional investor.Q32 Bio has entered into a definitive agreement for the issuance and sale of 1,666,679 shares of common stock and pre-funded warrants to purchase up to 1,025,654 shares of common stock at an offering price of $3.90 per share of common stock, which was the closing pric
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Q32 Bio Inc.SCHEDULE 13G/A - Q32 Bio Inc. (0001661998) (Subject)
- INSIDERSEC Form 4 filed by Director Grayzel David S.4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Lundberg Sven Ante4 - Q32 Bio Inc. (0001661998) (Issuer)